Cost-efficiency analysis of conversion to biosimilar filgrastim for supportive cancer care and resultant expanded access analysis to supportive care and early-stage HER2+ breast cancer treatment in Saudi Arabia: simulation study.

MLA

Yousef, Consuela Cheriece, et al. “Cost-Efficiency Analysis of Conversion to Biosimilar Filgrastim for Supportive Cancer Care and Resultant Expanded Access Analysis to Supportive Care and Early-Stage HER2+ Breast Cancer Treatment in Saudi Arabia: Simulation Study.” Journal of Medical Economics, vol. 26, no. 1, Jan. 2023, pp. 394–402. EBSCOhost, https://doi.org/10.1080/13696998.2023.2183680.

APA

Yousef, C. C., Khan, M. A., Almodaimegh, H., Alshamrani, M., Al-Foheidi, M., AlAbdalkarim, H., AlJedai, A., Naeem, A., & Abraham, I. (2023). Cost-efficiency analysis of conversion to biosimilar filgrastim for supportive cancer care and resultant expanded access analysis to supportive care and early-stage HER2+ breast cancer treatment in Saudi Arabia: simulation study. Journal of Medical Economics, 26(1), 394–402. https://doi.org/10.1080/13696998.2023.2183680

Chicago

Yousef, Consuela Cheriece, Mansoor Ahmed Khan, Hind Almodaimegh, Majed Alshamrani, Meteb Al-Foheidi, Hana AlAbdalkarim, Ahmed AlJedai, Anjum Naeem, and Ivo Abraham. 2023. “Cost-Efficiency Analysis of Conversion to Biosimilar Filgrastim for Supportive Cancer Care and Resultant Expanded Access Analysis to Supportive Care and Early-Stage HER2+ Breast Cancer Treatment in Saudi Arabia: Simulation Study.” Journal of Medical Economics 26 (1): 394–402. doi:10.1080/13696998.2023.2183680.